DECIPHERA PHARMACEUT

Item 7.01 Regulation FD Disclosure.

On January 10, 2022, Deciphera Pharmaceuticals, Inc. (the "Company") issued a
press release announcing corporate updates and highlighting key 2022 corporate
milestones. A copy of the press release is furnished herewith as Exhibit 99.1 to
this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K (including
Exhibit 99.1 attached hereto) is intended to be furnished and shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit No. Description

99.1 Press Release issued by Deciphera Pharmaceuticals, Inc. on
January 10, 2022, furnished herewith

104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses